How did ALNY's Q1 2025 EPS forecast compare to past trends?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is expected to report an EPS of $0.65 for Q1 2025, which is slightly below the consensus estimate of $0.62. Looking at the company's historical earnings performance, Alnylam has experienced a significant decrease in EPS from the previous quarter's $0.87 to the current quarter's $0.65. This trend indicates a challenging period for the company, and the negative EPS surprise suggests that the business may be facing unforeseen challenges or operational inefficiencies.

1. **Comparison with Consensus**: The EPS of $0.65 reported for Q1 2025 is a decrease from the previous quarter's EPS of $0.87, which is a clear indication that the company's performance is trending downwards. This trend is concerning for investors, as it suggests that the company may not be meeting market expectations.
2. **Analysis of Trends**: The 5-year EPS CAGR (Compound Annual Growth Rate) is not currently available. However, the significant drop in EPS from the previous quarter to the current quarter suggests that the company's earnings are not growing at a sustainable rate. This could be due to a variety of factors, including market conditions, company performance, or industry trends.

In conclusion, Alnylam Pharmaceuticals is facing a challenging period, as evidenced by the significant decrease in EPS from the previous quarter. The company's performance is trending downwards, which is a red flag for investors and suggests that the business may need to address operational inefficiencies or external challenges to improve its financial performance.